COVID-19 Pneumonia
Conditions
Brief summary
COVID-19 pneumonia manifests among others with a thick bronhial secretion. It contains an increased number of neutrophil extracellular traps (NETs), formed during netosis. DNA is a major component in NETs. DNAse alfa (Pulmozyme®, Roche) is a recombinant human enzyme, registered for inhalations in patients with Cystic fibrosis, in which NETs are also a typical characteristic. DNAse alfa inhalations are typically well tolerated and with no major side effects. Some initial reports exist of using DNAse alfa inhalations in COVID-19 patients, that had benefitial effects. There are some trials registered with ClinicalTrials, investigating the usufulness of DNAse alfa in intubated patients, but the investigators have no knowledge of a trial, investigating the usufulness of this drug in patients receiving High Flow Nasal Oxygen therapy.
Interventions
DRUGDornase Alfa
inhalations twice daily
DRUGSaline
inhalations twice daily
Sponsors
University Medical Centre Ljubljana
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Intervention model description
Double blind randomised
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Positive SARS-CoV-2 RNA PCR swab * inflamatory phase of infection * HFNO
Exclusion criteria
* pregnancy * previous treatment with DNAse alfa
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intubations | 7 days | Number of intubations necessary |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PaO2/FiO2 | 7 days | Increase in PaO2/FiO2 ratio |
| inflamation | 7 days | Reduction of inflamation |
Countries
Slovenia
Outcome results
None listed